Key clinical point: The use of glucocorticoids was associated with damage accrual independent of disease activity in patients with systemic lupus erythematosus (SLE).
Major finding: In both multivariable models, disease activity scores at baseline were independently associated with damage accrual (hazard ratios, 1.32 and 1.05; P = .0427 and P = .0012, respectively).
Study details: A prospective, longitudinal cohort study of 1,707 patients with SLE.
Disclosures: The study was funded by UCB Pharma, GlaxoSmithKline, Janssen, Bristol-Myers Squibb, and AstraZeneca. The authors reported financial affiliations with Abbott, AbbVie, Astellas, Ayumi Pharmaceutical, Bristol-Myers Squibb, Novartis, Pfizer, and several others.
Apostolopoulos D et al. Lancet Rheumatol. 2019 Nov 25. doi: 10.1016/S2665-9913(19)30105-5.